From July 21st to 23rd, 2025, Boston will host one of the most influential gatherings in the field of mRNA innovation: the mRNA-Based Therapeutics Summit USA.
read moreWe’re among the Alliance for Regenerative Medicine (ARM) leaders calling on the EU to act for the future of advanced therapies in Europe.
read moreWe’re excited to announce our participation in the BIO International Convention 2025, taking place from June 16–19 at the Boston Convention & Exhibition Center.
read moreWe are thrilled to announce our participation in the 64th AFI Symposium, taking place from June 11 to 13, 2025, at the Palacongressi di Rimini.
read moreAnemocyte, a biotech company at the forefront of advanced therapy development, is excited to join the upcoming international conference on gene therapy in Gaithersburg, MD.
read more
Altheia Science proudly announces the success of its strategic collaboration with Anemocyte, a leading developer and manufacturer of pDNA and mRNA headquartered in Italy.
read moreGenenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell based therapies
read moreAnemocyte is excited to announce its participation as an attendee at TIDES USA 2025, taking place from May 19–22, 2025, at the Manchester Grand Hyatt in San Diego, California.
read moreAnemocyte announces its sponsorship and exhibition at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), from May 13–17, 2025.
read moreAnemocyte is excited to announce its participation as an exhibitor at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, taking place from May 7 to 10 in New Orleans, Louisiana.
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
